NCT06275724
Specified Drug-use Survey of Leqvio for s.c. Injection.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 5 words
- Trial completed
- Primary completion date changed from estimate of Dec 17, 2026 to Nov 1, 2026
- Site details revised at 80 of 107 sites
- Minor Site details revised at 1 of 107 sitesv14
- Minor Study sites: 106 to 107v11
- Minor Study sites: 107 to 106v10
- Notable Primary and study completion dates: Dec 31, 2027 to Dec 17, 2026
- Enrollment target: 583 to 585
- Site details revised at 96 of 107 sites
Show 7 earlier versionsHide 7 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 560 to confirmed 583
- Site details revised at 107 of 107 sites
- Minor Study sites: 100 to 107v7
- Minor Study sites: 88 to 100v6
- Minor Study sites: 75 to 88v5
- Minor Study sites: 66 to 75v4
- Minor Study sites: 26 to 66v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 26
- Primary and study completion dates: Feb 28, 2028 to Dec 31, 2027
- Start date changed from estimate of Mar 31, 2024 to Mar 4, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of patients with adverse events
Timeframe: Up to 24 months
Numbers of patients with serious adverse events, adverse events by severity, and adverse drug reactions
Timeframe: Up to 24 months
Secondary (2)
Number of patients with adverse events leading to discontinuation of treatment with the product
Percent change from baseline in LDL-C levels
Arms and interventions
inclisiran
Patients prescribed with inclisiran
Other: inclisiran
Sites
107 sites in 1 country